Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A N Samko

Showing results (81-90 of 96) with videos related to

Pageof 10
Sort By:
Terapevticheskii Arkhiv|March 20, 2002
[Immediate and long-term results of implantation of the coronary stent "BioDiamond"]T A Batyraliev, A N Samko, I V Pershukov, et al.
Platelets|December 19, 2002
Safety, inhibition of platelet aggregation and pharmacokinetics of Fab'2 fragments of the anti-glycoprotein IIb-IIIa monoclonal antibody FRaMon in high-risk coronary angioplastyA V Mazurov, D V Pevzner, O A Antonova, et al.
Kardiologiia|August 11, 2005
[Long-term results of the use of TAIS coronary stent. Data of prospective follow-up for 18 months]A N Samko, I V Levitskiĭ, T A Batyraliev, et al.
Kardiologiia|May 20, 2006
[Disturbances of thyroid function after coronary angiography]V S Egorov, N Iu Sviridenko, N M Platonova, et al.
Kardiologiia|April 30, 2020
[The Incidence and Possible Predictors of Coronary Restenosis]A Yu Filatova, I V Romasov, A V Potekhina, et al.
Bulletin of Experimental Biology and Medicine|April 17, 2018
Pathological Remodeling of the Myocardium in Chronic Heart Failure: Role of PGC-1αT G Kulikova, O V Stepanova, A D Voronova, et al.
Kardiologiia|December 21, 2002
[Pharmacodynamics, safety, and clinical effects of a novel glycoprotein IIb/IIIa antagonist framon during high risk coronary angioplasty]A V Mazurov, D V Pevzner, A V Semenov, et al.
Kardiologiia|July 12, 2005
[Results of clinical trials of a novel glycoprotein IIb-IIIa antagonist framon in high-risk coronary angioplasty]A V Mazurov, D V Pevzner, I I Staroverov, et al.
Bulletin of Experimental Biology and Medicine|July 20, 2005
Low daily dose of antioxidant probucol decreases incidence and severity of restenosis after transluminal coronary balloon angioplastyA I Kaminnyi, V Z Lankin, A N Samko, et al.
Vestnik Rentgenologii I Radiologii|March 18, 2015
[Endovascular treatment for chronic coronary occlusions in patients with coronary heart disease]R O Shirokov, A N Samko, B I Milen'kin, et al.
Pageof 10

Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
Terapevticheskii Arkhiv|March 20, 2002
[Immediate and long-term results of implantation of the coronary stent "BioDiamond"]T A Batyraliev, A N Samko, I V Pershukov, et al.
Platelets|December 19, 2002
Safety, inhibition of platelet aggregation and pharmacokinetics of Fab'2 fragments of the anti-glycoprotein IIb-IIIa monoclonal antibody FRaMon in high-risk coronary angioplastyA V Mazurov, D V Pevzner, O A Antonova, et al.
Kardiologiia|August 11, 2005
[Long-term results of the use of TAIS coronary stent. Data of prospective follow-up for 18 months]A N Samko, I V Levitskiĭ, T A Batyraliev, et al.
Kardiologiia|May 20, 2006
[Disturbances of thyroid function after coronary angiography]V S Egorov, N Iu Sviridenko, N M Platonova, et al.
Kardiologiia|April 30, 2020
[The Incidence and Possible Predictors of Coronary Restenosis]A Yu Filatova, I V Romasov, A V Potekhina, et al.
Bulletin of Experimental Biology and Medicine|April 17, 2018
Pathological Remodeling of the Myocardium in Chronic Heart Failure: Role of PGC-1αT G Kulikova, O V Stepanova, A D Voronova, et al.
Kardiologiia|December 21, 2002
[Pharmacodynamics, safety, and clinical effects of a novel glycoprotein IIb/IIIa antagonist framon during high risk coronary angioplasty]A V Mazurov, D V Pevzner, A V Semenov, et al.
Kardiologiia|July 12, 2005
[Results of clinical trials of a novel glycoprotein IIb-IIIa antagonist framon in high-risk coronary angioplasty]A V Mazurov, D V Pevzner, I I Staroverov, et al.
Bulletin of Experimental Biology and Medicine|July 20, 2005
Low daily dose of antioxidant probucol decreases incidence and severity of restenosis after transluminal coronary balloon angioplastyA I Kaminnyi, V Z Lankin, A N Samko, et al.
Vestnik Rentgenologii I Radiologii|March 18, 2015
[Endovascular treatment for chronic coronary occlusions in patients with coronary heart disease]R O Shirokov, A N Samko, B I Milen'kin, et al.
Pageof 10